In a randomized, masked, placebo-controlled pilot of thirty-five cats with osteoarthritis, two infusions of donor stromal cells led to owner-rated treatment success in 78% to 83% of cats at 90 days, vs. 36.4% with saline.
In a placebo-controlled trial of 307 cats published Oct. 2, 2026, in The Veterinary Journal, relfovetmab, an anti-NGF antibody given every three months, led to treatment success in 73.0% of cats with osteoarthritis vs. 46.8% with placebo at day 90.
In a double-blind trial published Oct. 24, 2026, in The Veterinary Journal, a collagen hydrolysate-enriched diet didn't improve pain, function or gait in dogs with osteoarthritis over 12 weeks compared with a placebo diet; both groups seemed to improve.